Navigation Links
Scientists discover first gonorrhea strain resistant to all available antibiotics
Date:7/10/2011

An international research team has discovered a strain of gonorrhea resistant to all currently available antibiotics. This new strain is likely to transform a common and once easily treatable infection into a global threat to public health. The details of the discovery made by Dr. Magnus Unemo, Dr. Makoto Ohnishi, and colleagues will be presented at the 19th conference of the International Society for Sexually Transmitted Disease Research (ISSTDR) which runs July 10-13 in Quebec City, Canada.

The team of researchers successfully identified a heretofore unknown variant of the bacterium that causes gonorrhea, Neisseria gonorrhoeae. Analyzing this new strain, dubbed H041, allowed researchers to identify the genetic mutations responsible for the bacterium's extreme resistance to all cephalosporin-class antibioticsthe last remaining drugs still effective in treating gonorrhea.

"This is both an alarming and a predictable discovery," noted Dr. Unemo of the Swedish Reference Laboratory for Pathogenic Neisseria. "Since antibiotics became the standard treatment for gonorrhea in the 1940s, this bacterium has shown a remarkable capacity to develop resistance mechanisms to all drugs introduced to control it."

"While it is still too early to assess if this new strain has become widespread, the history of newly emergent resistance in the bacterium suggests that it may spread rapidly unless new drugs and effective treatment programs are developed," Dr. Unemo continued.

Gonorrhea is one of the most common sexually transmitted diseases in the world. In the U.S. alone, according to the Center for Disease Control and Prevention (CDC), the number of cases is estimated at 700,000 annually.

Gonorrhea is asymptomatic in about 50% of infected women and approximately 2-5% of men. When symptomatic, it is characterized by a burning sensation when urinating and pus discharge from the genitals. If left untreated, gonorrhea can lead to serious and irreversible health complications in both women and men.

In women, the infection can cause chronic pelvic pain and ectopic pregnancy. It can lead to infertility, mostly in women but also in men, and it increases the risk of HIV transmission. In 3-4% of cases, untreated infections spread to the skin, blood, joints, or even the heart and can cause potentially mortal lesions. Babies born of infected mothers are at high risk of developing serious blood and joint infections, and passage through the birth canal of an infected mother can cause blindness in the infant.


'/>"/>

Contact: Jean-Franois Hupp
jean-francois.huppe@dc.ulaval.ca
418-656-7785
Universit Laval
Source:Eurekalert

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Scientists identify novel inhibitor of human microRNA
3. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
4. MU scientists go green with gold, distribute environmentally friendly nanoparticles
5. Scientists identify gene that may contribute to improved rice yield
6. Scientists discover why a mothers high-fat diet contributes to obesity in her children
7. MU scientists see how HIV matures into an infection
8. Earth scientists keep an eye on Texas
9. Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability
10. Scientists identify a molecule that coordinates the movement of cells
11. Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology: